Becton, Dickinson and Company $BDX Shares Sold by Intech Investment Management LLC

Key Points

• Intech Investment Management LLC significantly reduced its stake in Becton, Dickinson and Company, selling 25,423 shares and decreasing its ownership by 46.2% in the first quarter.
• Becton, Dickinson and Company posted $3.68 EPS for the last quarter, surpassing analysts' expectations, with revenue increasing by 10.4% year-over-year.
• The firm announced a quarterly dividend of $1.04 per share, representing a yield of 2.2% and a payout ratio of 74.82%.

Intech Investment Management LLC trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 46.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,638 shares of the medical instruments supplier's stock after selling 25,423 shares during the period. Intech Investment Management LLC's holdings in Becton, Dickinson and Company were worth $6,789,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. GQG Partners LLC purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at about $689,833,000. Vanguard Group Inc. lifted its stake in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after purchasing an additional 1,259,750 shares during the period. Nuveen LLC bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $211,097,000. GAMMA Investing LLC raised its stake in Becton, Dickinson and Company by 29,654.0% during the 1st quarter. GAMMA Investing LLC now owns 744,445 shares of the medical instruments supplier's stock worth $170,523,000 after acquiring an additional 741,943 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after buying an additional 667,957 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BDX has been the subject of a number of recent research reports. Piper Sandler reissued a "neutral" rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Barclays reduced their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and decreased their price target for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $211.44.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,965 shares of company stock valued at $551,536 in the last quarter. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Up 0.7%

Shares of BDX traded up $1.38 during midday trading on Tuesday, hitting $187.12. The company had a trading volume of 636,403 shares, compared to its average volume of 2,559,029. The company's 50-day simple moving average is $186.72 and its 200-day simple moving average is $190.98. The firm has a market capitalization of $53.64 billion, a P/E ratio of 33.68, a P/E/G ratio of 1.51 and a beta of 0.27. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company's revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.